Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy

Rosell, 2001, Predictive molecular markers in non-small cell lung cancer, Curr. Opin. Oncol., 13, 101, 10.1097/00001622-200103000-00004

Georgoulias, 2001, Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial, Lancet, 357, 1478, 10.1016/S0140-6736(00)04644-4

Miller, 1995, New chemotherapeutic agents for non-small cell lung cancer, Chest, 107, 306S, 10.1378/chest.107.6_Supplement.306S

Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N. Engl. J. Med., 10, 92, 10.1056/NEJMoa011954

Lindahl, 1997, DNA excision repair pathways, Curr. Opin. Genet. Dev., 7, 158, 10.1016/S0959-437X(97)80124-4

Li, 2000, Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells, Anticancer Res., 20, 645

Lord, 2002, Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer, Clin. Cancer Res., 8, 2286

Vogel, 2000, DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes, Mutat. Res., 9, 197, 10.1016/S0921-8777(00)00051-3

Stanulla, 2000, Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case–control study, Blood, 15, 1222, 10.1182/blood.V95.4.1222.004k20_1222_1228

Rosell, 2002, Beta-tubulin mutational analysis: tantalizing findings, Lung Cancer, 38, 99, 10.1016/S0169-5002(02)00188-5

Kawakami, 2001, Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression, Clin. Cancer Res., 7, 4096

Krajinovic, 2002, Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia, Lancet, 359, 1033, 10.1016/S0140-6736(02)08065-0

Park, 2001, A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer, Cancer Res., 15, 8654

World Health Organization: WHO Hand Book for Reporting Results of Cancer Treatment, WHO Offset publication no. 48. Geneva, Switzerland: World Health Organization, 1979.

Dabholkar, 1994, Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy, J. Clin. Investig., 94, 703, 10.1172/JCI117388

Dabholkar, 1992, ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients, J. Natl. Cancer Inst., 84, 1512, 10.1093/jnci/84.19.1512

Shirota, 2001, ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy, J. Clin. Oncol., 1, 4298, 10.1200/JCO.2001.19.23.4298

Bosken, 2002, An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer, J. Natl. Cancer Inst., 17, 1091, 10.1093/jnci/94.14.1091

Yu, 2000, Comparison of two human ovarian carcinoma cell lines(A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene, Int. J. Oncol., 16, 555

Yu, 1997, A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues, Mutat. Res. Genom., 382, 13, 10.1016/S1383-5726(97)00004-6

Park, 2002, Lys751Gln polymorphism in the DNA repair gene XPD and risk of primary lung cancer, Lung Cancer, 36, 15, 10.1016/S0169-5002(01)00447-0

Chen, 2002, DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population, Carcinogenesis, 23, 1321, 10.1093/carcin/23.8.1321

Spitz, 2001, Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients, Cancer Res., 61, 1354